Pact shows promise for Medtronic and Alnylam
This article was originally published in Clinica
Executive Summary
A preclinical trial of the drug-device combination therapy for Huntington's disease developed under a collaboration between Medtronic and Alnylam Pharmaceuticals has yielded positive results, the companies said.